This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Through phylogenetic analysis and microscopy techniques, they identified a nuclear-encoded apicoplast RNA polymerase σ subunit called ApSigma. The study suggests that this regulatory system could be a potential target for future malaria treatments, offering hope for combatting this deadly disease that affects millions worldwide.
These factors are converging to enable both identification of novel infectious diseases as well as microbial resistance, before these threats can impact public health, write a team from the European Society for Clinical Microbiology and Infectious Diseases in Frontiers in Science. COVID clearly caught us off guard.
“Sam has an exceptional talent in software engineering, and his contributions reflect a deep understanding of both the technical and biological aspects required for bioinformatics tool development,” says Laura Luebbert, now a postdoctoral fellow in the Sabeti lab at the Broad Institute of MIT and Harvard and Harvard University.
With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine. She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures.
Among others, NGS has led to the identification of disease-causing variants and novel drug targets and an improved understanding of complex biological events, e.g., the heterogeneity of tumors. Methods of analysis include whole-genome sequencing (WGS), whole-exome sequencing (WES), and targeted sequencing.
With a background in biochemistry and bioinformatics, Lucy was interested in exploring how bioinformatics was applied to real-world healthcare data. I just graduated with a degree in Bioinformatics, and I was interested to see how the skills I learned could be applied.
Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. This is the third essay of four in our pandemic mini-issue.
This includes verifying the experimental design and understanding how the data was generated whether it was from RNA sequencing, mass spectrometry, or other biological assays. Figure 1: High-level workflow for early drug discovery Once the raw data has been gathered, the next step is to gain a thorough understanding of the data.
Made from a Cas9 nickase (the histidine at amino acid position 840 is swapped for an alanine) fused to a reverse transcriptase enzyme (which makes DNA from RNA; transcription in reverse), prime editing clinical trials are expected to begin by 2025. Early targets may include sickle-cell disease, Friedrich’s ataxia, and cystic fibrosis.
Made from a Cas9 nickase (the histidine at amino acid position 840 is swapped for an alanine) fused to a reverse transcriptase enzyme (which makes DNA from RNA; transcription in reverse), prime editing clinical trials are expected to begin by 2025. Early targets may include sickle-cell disease, Friedrich’s ataxia, and cystic fibrosis.
A concerned employee at a laboratory supply company had called the Centers for Disease Control, or CDC, after fielding repeated calls from Harris asking when his samples of plague would arrive in the mail. 5 But it could match up to one of the threats in your reference database, so you opt to throw a battery of bioinformatics tools at it.
BMC Bioinformatics. Read An RNA-based system to study hepatitis B virus replication and evaluate antivirals. Read [Comment] Delivering the next generation of cancer immunotherapies with RNA. The Lancet Infectious Diseases. The Lancet Infectious Diseases. Comparison of transformations for single-cell RNA-seq data.
Drug Discovery Today: Disease Models (2008). Link A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , by Jinek M. Link Artificial Gene Regulatory Networks—A Review , by Cussat-Blanc S. Artificial Life (2018). Link Mathematical modeling and synthetic biology , by Chandran D. & Charpentier E.
Drug Discovery Today: Disease Models (2008). Link A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , by Jinek M. Link In vitro integration of ribosomal RNA synthesis, ribosome assembly, and translation , by Jewett M.C. Artificial Life (2018). & Charpentier E.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content